SSY GROUP (02005.HK): Trustee Purchases 900,000 Shares for Approximately HKD 2,414,700 under Restricted Share Award Scheme
NewTimeSpace News: On 31 August 2026, SSY Group Limited (stock code: 02005) issued a voluntary announcement that, pursuant to the restricted share award scheme adopted by the Company on 27 December 2018, the trustee of the scheme purchased an aggregate of 900,000 shares of the Company in the open market on the same day, funded by the Company's internal resources, and holds such shares in trust for selected participants.
According to the announcement, the shares purchased by the trustee represented approximately 0.030% of the total issued shares of the Company, with an average consideration of approximately HKD 2.6830 per share (excluding expenses) and an aggregate consideration of approximately HKD 2,414,700 (excluding expenses); immediately after the purchase, the trustee held a balance of 13,180,000 shares, representing approximately 0.447% of the total issued shares of the Company.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SSY GROUP (02005.HK): Gadobutrol injection and indocyanine green for injection approved, enhancing imaging and critical care product portfolio
- SSY GROUP(02005.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 320.32 million, YoY increase of 12.99%
- SSY GROUP (02005.HK): Obtains production registration approval for sodium ozagrel injection, achieving full dosage form coverage
- SSY GROUP (02005.HK): Vitamin K1 Injection obtains NMPA drug production registration certificate, deemed to pass consistency evaluation
- SSY GROUP (02005.HK): Four Products Receive NMPA Drug Manufacturing Registration Approvals, Deepening Infusion Therapy and Ophthalmology Portfolio